Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Daratumumab (Primary) ; Nivolumab (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jul 2017 Planned End Date changed from 17 Oct 2020 to 23 Oct 2020.
- 10 Jul 2017 Planned primary completion date changed from 9 Jun 2019 to 16 Jun 2019.
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.